Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Liabilities (2018 - 2025)

Sangamo Therapeutics (SGMO) has 10 years of Other Non-Current Liabilities data on record, last reported at $977000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities fell 21.27% year-over-year to $977000.0; the TTM value through Sep 2025 reached $977000.0, down 21.27%, while the annual FY2024 figure was $933000.0, 21.4% down from the prior year.
  • Other Non-Current Liabilities reached $977000.0 in Q3 2025 per SGMO's latest filing, up from $962000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $7.6 million in Q3 2021 and bottomed at $933000.0 in Q4 2024.
  • Average Other Non-Current Liabilities over 5 years is $2.2 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: grew 22.93% in 2021, then crashed 82.9% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.2 million in 2021, then fell by 0.82% to $1.2 million in 2022, then fell by 1.66% to $1.2 million in 2023, then dropped by 21.4% to $933000.0 in 2024, then increased by 4.72% to $977000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $977000.0 in Q3 2025, $962000.0 in Q2 2025, and $933000.0 in Q1 2025.